Considering that the only antiobesity drug approved by the Food and Drug Administration (FDA) is a pancreatic lipase inhibitor (orlistat), the importance of discovering new and potent inhibitors for the enzyme is better understood.[16] It has been reported that there will be a need to find new therapeutics due to the expected increase in Alzheimer's disease (AD) cases. This evidence concerns the gene PNLIP and Alzheimer disease.